Tradegate
15.12.25 | 15:51
27,140 Euro
+1,34 % +0,360
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 26,400 | 26,480 | 10:37 | |
| 26,400 | 26,480 | 10:34 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.12. | Medincell: Starkes Umsatzwachstum, doch anhaltende Verluste belasten den Aktienkurs | 1 | Investing.com Deutsch | ||
| MEDINCELL Aktie jetzt für 0€ handeln | |||||
| 09.12. | Medincell Publishes its Consolidated Half-Year Financial Results | 237 | Business Wire | (April 1st, 2025 September30, 2025)
Regulatory News:
Christophe Douat, CEO of Medincell (Paris:MEDCL)"We are pleased with the company's growth and momentum. We have entered the most transformative... ► Artikel lesen | |
| 09.12. | Medincell's Partner Teva Pharmaceuticals Announces the New Drug Application1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults | 284 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad... ► Artikel lesen | |
| 01.12. | Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025 | 259 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 9, 2025 to present the half-year financial results (April 2025-September 2025)
Meeting in French, 6:00... ► Artikel lesen | |
| 27.11. | Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference | 368 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Christophe Douat, Chief Executive Officer, Dr. Richard Malamut, Chief Medical Officer, and Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will... ► Artikel lesen | |
| 24.11. | Medincell Awarded New Grant to Fight Malaria | 250 | Business Wire | Medincell to receive a $3 million grant from the Gates Foundation to advance mdc-STM malaria program. mdc-STM program is an investigational, three-month, subcutaneous injectable formulation of... ► Artikel lesen | |
| 13.11. | Medincell Management to Participate in Fireside Chat at the Jefferies London Healthcare Conference 2025 (London - Nov. 17-20, 2025) | 303 | Business Wire | Regulatory News:
Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell's (Paris:MEDCL) corporate overview during a fireside chat at the... ► Artikel lesen | |
| 11.11. | Medincell Promotes Grace Kim Chief Strategy Officer U.S. Finance | 1 | Contract Pharma | ||
| 11.11. | Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth | 300 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL), a clinical-stage pharmaceutical company pioneering long-acting injectable therapies, today announced the expanded role of Dr Grace Kim, Chief Strategy... ► Artikel lesen | |
| 10.11. | Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark | 285 | Business Wire | Medincell has been selected for inclusion in the Morgan Stanley Capital International (MSCI) World Small Cap Index, which encompasses the most liquid and high-performing small-cap companies across... ► Artikel lesen | |
| 06.11. | Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York) | 351 | Business Wire | Regulatory News:
Dr Grace Kim, Chief Strategy Officer, U.S. Finance, and Dr Richard Malamut, Chief Medical Officer, will speak on Medincell's (Paris:MEDCL) value proposition, including recent... ► Artikel lesen | |
| 05.11. | Medincell: UZEDY Continues Strong Growth; Teva Setting the Stage for US NDA Submission for Olanzapine LAI in Q4 2025 | 425 | Business Wire | Regulatory News:
Medincell's (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information:
About Olanzapine Long-Acting Injectable (TEV-749 mdc-TJK)
1-Month subcutaneous... ► Artikel lesen | |
| 22.10. | Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York) | 299 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will speak on Medincell's value proposition, including recent developments and meet with investors... ► Artikel lesen | |
| 13.10. | FDA approves Teva and Medincell's bipolar I disorder treatment | 27 | Pharmaceutical Technology | ||
| 10.10. | Medincell: FDA Approves Expanded Indication for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder | 446 | Business Wire | FDA approves UZEDY (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar... ► Artikel lesen | |
| 23.09. | Teva and Medincell's Risperidone LAI Approved in Canada as LONGAVO | 531 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Teva Canada Limited, a subsidiary of Medincell's partner Teva Pharmaceutical Industries Ltd., has received regulatory approval for risperidone LAI... ► Artikel lesen | |
| 22.09. | Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed | 383 | AFX News | PETAH TIKVA (dpa-AFX) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first... ► Artikel lesen | |
| 22.09. | Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile - No PDSS Observed | 388 | Business Wire | There were no suspected or confirmed PDSS (Post-injection Delirium/Sedation Syndrome)1 events observed with Medincell's Olanzapine LAI through week 56 in the pivotal Phase 3 SOLARIS trial2 The... ► Artikel lesen | |
| 22.09. | Medincell: New Data Show that UZEDY Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna | 372 | Business Wire | UZEDY was associated with a 2.89-day shorter length of hospital stay compared with Invega Sustenna (paliperidone palmitate) This translates to estimated direct cost savings of $3200 per hospitalization... ► Artikel lesen | |
| 17.09. | Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation | 555 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 21, 2025,... ► Artikel lesen |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,95 | +0,19 % | Märkte am Morgen: Nvidia, Netflix, Paramount Skydance, Bayer, HelloFresh, BioNTech, ASML | Die Sitzung der US-Notenbank am Mittwoch ist das beherrschende Thema in dieser Woche. Am deutschen Aktienmarkt zeigte sich der DAX im Vorfeld zurückhaltend, schloss aber immerhin leicht in der Gewinnzone.... ► Artikel lesen | |
| EVOTEC | 5,126 | -1,23 % | DAX-Check LIVE: Evotec, Jost Werke, MBB, Nordex, Rheinmetall, Thyssenkrupp, Vonovia im Fokus | Zum Wochenstart konnte der DAX seine anfänglichen Gewinne nicht halten. Vor der am Mittwoch anstehenden Zinssitzung der US-Notenbank Fed agierten die Anleger vorsichtig. Der Leitindex blieb jedoch knapp... ► Artikel lesen | |
| MEDIGENE | 0,023 | -22,82 % | MEDIGENE AG stürzt ab - ich traue meinen Augen nicht! | ||
| QIAGEN | 38,510 | +0,46 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| CUREVAC | 4,172 | -2,48 % | EILMELDUNG: Curevac-Aktie verliert deutlich - bricht jetzt das Vertrauen weg? | ||
| MODERNA | 25,195 | -1,10 % | Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE | mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the... ► Artikel lesen | |
| VALNEVA | 3,690 | -0,65 % | Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ | IXCHIQ- was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups... ► Artikel lesen | |
| AMGEN | 275,55 | -0,47 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,551 | -0,95 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| STRYKER | 299,40 | 0,00 % | Medizintechnik-Anbieter Stryker hebt erneut Dividende an | ||
| BIOGEN | 147,75 | -1,17 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| BIOFRONTERA | 2,560 | -4,12 % | BIOFRONTERA AG: Jetzt kippt das Gleichgewicht! | ||
| HEIDELBERG PHARMA | 2,700 | -0,37 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma gibt Veränderungen im Vorstand bekannt - Dr. Dongzhou Jeffery Liu wird Mitglied des Vorstands und Vorstandsvorsitzender | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Personalie
Heidelberg Pharma gibt Veränderungen im Vorstand bekannt - Dr. Dongzhou Jeffery Liu wird Mitglied des Vorstands und... ► Artikel lesen | |
| ILLUMINA | 113,60 | -1,03 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| IMMUNOME | 22,640 | 0,00 % | Why Immunome Stock Surged Today |
MEDINCELL SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,360 (+1,34 %) liegt der Kurs bei 27,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDINCELL SA finden Sie auf Wallstreet Online.